FDA Approves Leqembi Iqlik (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
BLA FilingapprovedLeqembi IqlikPositive
AI Analysis
Summary
FDA approves supplemental Biologics License Application for Leqembi Iqlik (lecanemab-irmb) subcutaneous injection as an initiation dose for early Alzheimer's disease, jointly developed by Eisai and Biogen.
Outcome Details
FDA approved supplemental Biologics License Application (sBLA) for subcutaneous injection as initiation dose
Importance:8/10
Sentiment:
0.90
FDA approvalAlzheimer's diseaseLecanemabSubcutaneous injectionSupplemental BLA
Read the original article
Published by Drugs.com New Drug Approvals on July 13, 2026 12:07 AM